Truist Financial Lowers DaVita (NYSE:DVA) Price Target to $128.00

DaVita (NYSE:DVA) had its target price cut by analysts at Truist Financial from $140.00 to $128.00 in a report issued on Monday,MarketScreener reports. The firm currently has a “hold” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 11.65% from the company’s current price.

A number of other research firms have also weighed in on DVA. Cowen reissued a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Zacks Research upgraded shares of DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. Wall Street Zen lowered shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Barclays cut their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research note on Thursday, October 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, DaVita presently has an average rating of “Hold” and an average price target of $145.60.

DaVita Trading Up 0.6%

NYSE DVA opened at $114.65 on Monday. The firm has a market capitalization of $8.09 billion, a P/E ratio of 11.81, a price-to-earnings-growth ratio of 0.70 and a beta of 0.99. The firm’s fifty day moving average price is $118.24 and its two-hundred day moving average price is $129.48. DaVita has a 1 year low of $111.43 and a 1 year high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. During the same quarter in the prior year, the firm earned $2.59 earnings per share. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, research analysts anticipate that DaVita will post 10.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Hantz Financial Services Inc. lifted its stake in DaVita by 48.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. MAI Capital Management increased its holdings in shares of DaVita by 23.4% during the second quarter. MAI Capital Management now owns 438 shares of the company’s stock worth $62,000 after buying an additional 83 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of DaVita by 1.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after acquiring an additional 94 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its position in DaVita by 34.9% during the 3rd quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock worth $59,000 after acquiring an additional 117 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.